Towards a protocol for the preparation and delivery of striatal tissue for clinical trials of transplantation in Huntington's disease.
There is a growing body of scientific evidence contributing to the development of clinical transplantation programs in patients with Huntington's disease. Phase I clinical trials have already commenced in France and North America and are starting in the near future in Sweden and the UK. Protocols for patient selection, surgical implantation, and pre- and postoperative follow-up are well defined. However, considerable variability exists with respect to the harvesting, preparation, and timing of implantation of the donor material. In this article we review the scientific evidence on which a rational protocol for donor tissue preparation and delivery may be based. Strategies aimed at minimizing the variability of tissue preparation should reduce the variability of functional outcome of striatal transplantation observed in animal models of Huntington's disease.
Watts
C
C
MRC Cambridge Centre for Brain Repair, Department of Neurosurgery, University of Cambridge, UK. cw209@cam.ac.uk
Dunnett
S B
SB
D000818:Animals; D016380:Brain Tissue Transplantation / Q000379:methods*; D017690:Cell Transplantation / Q000379:methods; D002985:Clinical Protocols; D002986:Clinical Trials as Topic; D003342:Corpus Striatum / Q000166:cytology / Q000637:transplantation*; D004195:Disease Models, Animal; D016332:Fetal Tissue Transplantation / Q000379:methods*; D005865:Gestational Age; D006801:Humans; D006816:Huntington Disease / Q000473:pathology / Q000503:physiopathology / Q000601:surgery*; D014019:Tissue Donors